QuidelOrtho (QDEL) to Release Quarterly Earnings on Thursday

QuidelOrtho (NASDAQ:QDEL) is set to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce earnings of $0.30 per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

QuidelOrtho Price Performance

QuidelOrtho stock opened at $39.09 on Tuesday. QuidelOrtho has a 52 week low of $29.74 and a 52 week high of $75.86. The company has a current ratio of 1.44, a quick ratio of 0.79 and a debt-to-equity ratio of 0.70. The firm’s 50-day simple moving average is $42.51 and its 200 day simple moving average is $40.44.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on QDEL shares. UBS Group started coverage on shares of QuidelOrtho in a research report on Thursday, September 19th. They issued a “neutral” rating and a $50.00 price objective on the stock. Craig Hallum upgraded shares of QuidelOrtho from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $40.00 to $57.00 in a research report on Thursday, September 5th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $61.00 price objective on shares of QuidelOrtho in a research report on Friday, August 16th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $58.83.

Insider Activity at QuidelOrtho

In related news, major shareholder Carlyle Group Inc. sold 78,180 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $39.94, for a total value of $3,122,509.20. Following the completion of the transaction, the insider now owns 8,441,022 shares of the company’s stock, valued at approximately $337,134,418.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.00% of the stock is currently owned by corporate insiders.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.